By Lorie Szymela - Research Director, Central Alabama Research
It’s flu season, and many Alabama providers are facing challenges prescribing Xofluza with out-of-stock alerts at the pharmacy and high co-pays. Central Alabama Research is currently enrolling for flu clinical research trials, featuring the cutting-edge Xofluza, and we need your expertise.
Referring your patient to a clinical trial can be a crucial step in offering them cutting-edge treatments and expanding the scope of medical knowledge.
Your support could be the game-changer in the fight against influenza. There is no cost to the patient and compensation for time and travel is provided. To learn more about our influenza trials, go to www.centralalabamaresearch.com or call 205-949-1907. If you would like to have patient information available in your clinic for the current enrolling studies, please email Lszymela@centralalabamarsearch.com
- A Surveillance Study of Susceptibility to Baloxavir Marboxil in Participants with Influenza (Pebblestone) Ages 1-11, Compensation $480, and patients free flu testing and if positive, receive Xofluza onsite at no cost. (No blood draws, only nasal swab collection while on study.)
- Study to Assess the Efficacy of Baloxavir Marboxil vs. Placebo to Reduce Onward Transmission of Influenzas A or B in Households (Centerstone). Ages 2 – 64, free flu testing and if positive receive Xofluza or placebo onsite, compensation up to $975 for a family of four. Study duration nine days. (No blood draws, only nasal swab collection while on study.)
About Xofluza:
Xofluza, an antiviral medication, has emerged as a game-changer in the treatment of influenza, offering a swift and effective response to the flu virus. Unlike traditional antiviral drugs, Xofluza operates by inhibiting the activity of a key enzyme necessary for the influenza virus to replicate within the body.
What sets Xofluza apart is its remarkable speed in alleviating symptoms and curbing the duration of the flu. Administered as a single oral dose, usually within 48 hours of symptom onset, Xofluza interrupts the virus's ability to spread, reducing the severity and duration of flu symptoms.
Additionally, Xofluza demonstrates an impressive spectrum of efficacy, proving effective against a broad range of influenza viruses, including those resistant to other antiviral medications.
Central Alabama Research, located at 10 Old Montgomery Highway Birmingham, AL 35209 is open 7 days a week, including holidays. 24 patient line for appointments is 205-432-9221.